Share

March 01, 2022; 98 (9) Research Article

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

Melanie D. Whittington, Jonathan D. Campbell, David Rind, Noemi Fluetsch, Grace A. Lin, Steven D. Pearson
First published January 12, 2022, DOI: https://doi.org/10.1212/WNL.0000000000013314
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
408

Share

Article Information

vol. 98 no. 9 e968-e977
DOI: 
https://doi.org/10.1212/WNL.0000000000013314
PubMed: 
35022306
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received September 13, 2021
  • Accepted in final form December 29, 2021
  • First Published January 12, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Melanie D. Whittington, PhD,
    2. Jonathan D. Campbell, PhD,
    3. David Rind, MD, MSc,
    4. Noemi Fluetsch, MSc, MPH,
    5. Grace A. Lin, MD and
    6. Steven D. Pearson, MD, MSc
  1. Melanie D. Whittington, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Merck, (2) Ipsen Biophamaceuticals, (3) GalbraithWight All three consultancies were prior to my current employment at the Institute for Clinical and Economic Review.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Veteran's Health Administration

    Research Support, Academic Entities:

    1. (1) University of Colorado Anschutz Medical Campus (2) University of Kansas Medical Center

    Research Support, Foundations and Societies:

    1. (1) PhRMA Foundation, (2) Arnold Ventures, (3) The Patrick and Catherine Weldon Donaghue Medical Research Foundation, (4) Kaiser Foundation Health Plan Inc.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Jonathan D. Campbell, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Merck and Company, (2) Ipsen Pharmaceuticals, (3) Institute for Clinical and Economic Review (prior to employment).

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. ICER received financial support for non-assessment activities from the following entities: (1) Aetna, (2) America's Health Insurance Plans, (3) Anthem, (4) AbbVie, (5) Alnylam, (6) AstraZeneca, (7) Biogen, (8) Blue Shield of CA, (9) Cambia Health Services, (10) CVS, (11) Editas, (12) Express Scripts, (13) Genentech/Roche, (14) GlaxoSmithKline, (15) Harvard Pilgrim, (16) Health Care Service Corporation, (17) Health Partners, (18) Johnson & Johnson (Janssen), (19) Kaiser Permanente, (20) LEO Pharma, (21) Mallinckrodt, (22) Merck, (23) Novartis, (24) National Pharmaceutical Council, (25) Premera, (26) Prime Therapeutics, (27) Regeneron, (28) Sanofi, (29) Spark Therapeutics, (30) United Healthcare, (31) HealthFirst, (32) Prizer, (33) Boehringer-Ingelheim, (34) uniQure, (35) Evolve Pharmacy Solutions, (36) Humana, (37) Sun Life.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. ICER received grants from: (1) Arnold Ventures, (2) Kaiser Foundation Health Plan Inc., (3) The Patrick and Catherine Weldon Donaghue Medical Research Foundation. Dr. Campbell received grant funding from PhRMA Foundation while on faculty at University of Colorado, prior to joining ICER.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. David Rind, MD, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. UpToDate, Wolters Kluwer, ongoing

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I am an employee of the Institute for Clinical and Economic Review, and independent not-for-profit organization. ICER receives funds for an annual policy summit from the following organizations: • AbbVie • Alnylam Pharmaceuticals • America’s Health Insurance Plans (AHIP) • Anthem • AstraZeneca • Biogen • Blue Shield of CA • Boehringer Ingelheim • CVS Caremark • Envolve Pharmacy Solutions • Express Scripts • Genentech • GlaxoSmithKline • Harvard Pilgrim Health Care • Health Care Service Corporation (HCSC) • Humana • Kaiser Permanente • LEO Pharma • Mallinckrodt Pharmaceuticals • Merck & Co. • National Pharmaceutical Council (NPC) • Novartis • Pfizer • Premera Blue Cross • Prime Therapeutics • Regeneron • Sanofi • Sun Life Financial • United Healthcare • uniQure

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. Commonwealth of Massachusetts, HPC-2020-001- PharmPricing, 2020-2021 2. US Department of Veterans Affairs, 36C24E20C0014, 2020-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. California Health Care Foundation 2. Kaiser Foundation Health Plan Inc. 3. Laura and John Arnold Foundation 4. Patrick and Catherine Weldon Donaghue Medical Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Noemi Fluetsch, MSc, MPH,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Grace A. Lin, MD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. JAMA Internal Medicine, Editorial Board Member, 2013-present. 2. Circulation: Cardiovascular Quality and Outcomes, 2017-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. 1. National Institutes of Health - National Cancer Institute R01CA221870-03S1 2. National Institutes of Health - NHGRI R01HG011792

    Research Support, Foundations and Societies:

    1. Institute for Clinical and Economic Review

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Steven D. Pearson, MD, MSc
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dues received for annual Policy Summit put on by my organization from: AbbVie Alnylam Pharmaceuticals America’s Health Insurance Plans (AHIP) Anthem AstraZeneca Biogen Blue Shield of CA Boehringer Ingelheim CVS Caremark Envolve Pharmacy Solutions Express Scripts Genentech GlaxoSmithKline Harvard Pilgrim Health Care Health Care Service Corporation (HCSC) Humana Kaiser Permanente LEO Pharma Mallinckrodt Pharmaceuticals Merck & Co. National Pharmaceutical Council (NPC) Novartis Pfizer Premera Blue Cross Prime Therapeutics Regeneron Sanofi Sun Life Financial United Healthcare uniQure

    Research Support, Government Entities:

    1. Commonwealth of Massachusetts, HPC-2020-001-PharmPricing, 2020-2021 US Department of Veterans Affairs, 36C24E20C0014, 2020-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. California Health Care Foundation Kaiser Foundation Health Plan Inc. Laura and John Arnold Foundation Patrick and Catherine Weldon Donaghue Medical Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute For Clinical and Economic Review (M.D.W., J.D.C., D.R., N.F., G.A.L., S.D.P.), Boston, MA; and Department of Medicine (G.A.L.), University of California San Francisco.
  1. Correspondence
    Dr. Whittington mwhittington{at}icer.org
View Full Text

Article usage

Article usage: January 2022 to April 2022

AbstractFullPdfSource
Jan 20222413099Highwire
Feb 202210732375Highwire
Mar 2022134772157Highwire
Apr 20226743877Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me